Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SANFORD M WOLFE

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1255390233
CMS profile
11658
Location
DAYTON, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$2,181.38

139 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,094.31 137
Education $87.07 2

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
ABBVIE INC. $382.64 20
Janssen Biotech, Inc. $372.28 27
Amgen Inc. $365.99 23
Novartis Pharmaceuticals Corporation $237.37 8
UCB, Inc. $203.98 23
AstraZeneca Pharmaceuticals LP $167.76 9
Janssen Scientific Affairs, LLC $124.98 1
PFIZER INC. $122.14 17
Exeltis, USA Inc. $67.29 3
Lilly USA, LLC $54.99 3
Radius Health, Inc. $53.69 3
GlaxoSmithKline, LLC. $28.27 2

Page 2 of 3; records 51–100 of 139 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SANFORD M WOLFE

NPI 1255390233 · CMS profile ID 11658

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

DAYTON, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 139 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1255390233?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SANFORD M WOLFE, NPI 1255390233, CMS profile ID 11658. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 139 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1255390233?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). SANFORD M WOLFE, NPI 1255390233, CMS profile ID 11658. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 139 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1255390233?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
SANFORD M WOLFE, NPI 1255390233, CMS profile ID 11658, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 139 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1255390233?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

139 matching records · $2,181.38 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 139 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 139.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $31.4408/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893226961 CMS
Amgen Inc. $25.6408/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939315575 CMS
Janssen Biotech, Inc. $4.2108/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886354895 CMS
Novartis Pharmaceuticals Corporation $22.7308/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894455227 CMS
AstraZeneca Pharmaceuticals LP $21.1308/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915524287 CMS
Janssen Biotech, Inc. $15.7108/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886354845 CMS
ABBVIE INC. $3.1908/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893226957 CMS
ABBVIE INC. $8.4908/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893226959 CMS
PFIZER INC. $7.3108/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949314557 CMS
PFIZER INC. $3.7608/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949327791 CMS
Lilly USA, LLC $17.3607/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918364343 CMS
AstraZeneca Pharmaceuticals LP $18.5807/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914856747 CMS
Amgen Inc. $4.4607/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939315595 CMS
AstraZeneca Pharmaceuticals LP $16.0007/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915561379 CMS
ABBVIE INC. $27.2007/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893226955 CMS
Exeltis, USA Inc. $19.9607/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947122661 CMS
Amgen Inc. $22.7106/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939315589 CMS
UCB, Inc. $24.5306/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 965174351 CMS
Novartis Pharmaceuticals Corporation $60.3706/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894455215 CMS
UCB, Inc. $13.3706/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 965174345 CMS
ABBVIE INC. $3.0106/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893226951 CMS
ABBVIE INC. $25.8606/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893226953 CMS
Amgen Inc. $17.3406/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939315567 CMS
UCB, Inc. $6.4006/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 965174335 CMS
Janssen Biotech, Inc. $66.9906/07/2022 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886354839 CMS
PFIZER INC. $5.1806/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949323925 CMS
PFIZER INC. $4.0905/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949328823 CMS
UCB, Inc. $5.2005/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 965170501 CMS
UCB, Inc. $5.1605/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 965170499 CMS
AstraZeneca Pharmaceuticals LP $19.6905/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914968349 CMS
Novartis Pharmaceuticals Corporation $15.9105/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894455219 CMS
Janssen Biotech, Inc. $12.2905/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886354945 CMS
Amgen Inc. $21.6704/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939315565 CMS
PFIZER INC. $17.0104/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949102755 CMS
ABBVIE INC. $28.2904/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893226949 CMS
PFIZER INC. $1.3004/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949342973 CMS
UCB, Inc. $5.4804/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 965170503 CMS
Janssen Biotech, Inc. $25.1704/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886354885 CMS
Janssen Biotech, Inc. $3.8904/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886354891 CMS
UCB, Inc. $5.8704/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 965174331 CMS
UCB, Inc. $7.4204/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 965174337 CMS
Amgen Inc. $10.6804/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939890457 CMS
PFIZER INC. $15.0904/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949119669 CMS
UCB, Inc. $5.7604/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 965170507 CMS
AstraZeneca Pharmaceuticals LP $23.6004/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914778839 CMS
Janssen Biotech, Inc. $20.2503/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886354833 CMS
Amgen Inc. $6.6703/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939315573 CMS
Novartis Pharmaceuticals Corporation $63.9703/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894455217 CMS
Novartis Pharmaceuticals Corporation $17.0803/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894455225 CMS
Amgen Inc. $9.3203/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939315593 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $10,159.48 108
PY2020 $1,243.91 80
PY2021 $2,214.75 150
PY2022 $2,181.38 139
PY2023 $2,683.00 136
PY2024 $1,482.79 73
PY2025 $849.45 18

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $479,998.80 19
PY2024 Principal investigator $497,894.87 18
PY2023 Principal investigator $468,972.96 37
PY2022 Principal investigator $650,288.22 245
PY2021 Principal investigator $748,972.15 158
PY2020 Principal investigator $1,137,813.55 102
PY2019 Principal investigator $670,497.46 88

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

19 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $23,714.00 11/19/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH LLC
PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND,PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF SIBEPRENLIMAB ADMINISTERED SUBCUTANEOUSLY IN SUBJECTS WITH ACTIVE PRIMARY SJGRENS SYNDROME (PSS) No dispute reported 06/30/2026 1225336263
Principal investigator 1 Novartis Pharmaceuticals Corporation $45.32 11/15/2025 Non-covered Recipient Entity
STAT RESEARCH INC
A Randomized, Double-blind, Placebo Controlled, 2-arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ianalumab in Patients With Active Sjogren's Syndrome (NEPTUNUS-1) No dispute reported 06/30/2026 1190310228
Principal investigator 1 Novartis Pharmaceuticals Corporation $289.18 10/08/2025 Non-covered Recipient Entity
STAT RESEARCH INC
A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjogrens syndrome No dispute reported 06/30/2026 1190310232
Principal investigator 1 Amgen Inc. $1,637.13 07/28/2025 Non-covered Recipient Entity
STAT RESEARCH
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246648704
Principal investigator 1 UCB SA $11,208.22 06/27/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS No dispute reported 06/30/2026 1246658596
Principal investigator 1 Amgen Inc. $18,126.63 06/12/2025 Non-covered Recipient Entity
STAT RESEARCH
A Multicenter, Open-Label, Long-term, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants With Sjgren's Syndrome (SS) No dispute reported 06/30/2026 1246648699
Principal investigator 1 Amgen Inc. $34,900.36 05/21/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH, INC.
A Multicenter, Open-Label, Long-term, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants With Sjgren's Syndrome (SS) No dispute reported 06/30/2026 1246646717
Principal investigator 1 Amgen Inc. $67,454.00 04/25/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH LLC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246646708
Principal investigator 1 UCB SA $31,774.00 04/09/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH
A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. No dispute reported 06/30/2026 1246659412
Principal investigator 1 Amgen Inc. $138,061.09 04/02/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH, INC.
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246646724
Principal investigator 1 Novartis Pharmaceuticals Corporation $9,602.00 03/25/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH DBA STAT RESEARCH
A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SL No dispute reported 06/30/2026 1190309748
Principal investigator 1 Amgen Inc. $2,983.49 03/17/2025 Non-covered Recipient Entity
DM CLINICAL RESEARCH-ERN-PPDS
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246640853
Principal investigator 1 Amgen Inc. $11,704.23 03/12/2025 Non-covered Recipient Entity
STAT RESEARCH-600 AVIATOR CT
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgrens Syndrome With Moderate-to-Severe Systemic Disease Activity No dispute reported 06/30/2026 1246648695
Principal investigator 1 Novartis Pharmaceuticals Corporation $37,457.86 02/10/2025 Non-covered Recipient Entity
STAT RESEARCH INC
A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjogrens syndrome No dispute reported 06/30/2026 1190310234
Principal investigator 1 Novartis Pharmaceuticals Corporation $8,011.09 01/30/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH DBA STAT RESEARCH
A Randomized, Double-blind, Placebo Controlled, 2-arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ianalumab in Patients With Active Sjogren's Syndrome (NEPTUNUS-1) No dispute reported 06/30/2026 1190309744
Principal investigator 1 Novartis Pharmaceuticals Corporation $49,240.30 01/28/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH DBA STAT RESEARCH
A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjogrens syndrome No dispute reported 06/30/2026 1190309746
Principal investigator 1 Amgen Inc. $12,324.11 01/22/2025 Non-covered Recipient Entity
STAT RESEARCH-600 AVIATOR CT
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants with Sjgrens Syndrome With Moderate-to-Severe Symptom State No dispute reported 06/30/2026 1246648692
Principal investigator 1 Novartis Pharmaceuticals Corporation $14,802.68 01/15/2025 Non-covered Recipient Entity
STAT RESEARCH INC
A Randomized, Double-blind, Placebo Controlled, 2-arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ianalumab in Patients With Active Sjogren's Syndrome (NEPTUNUS-1) No dispute reported 06/30/2026 1190310230
Principal investigator 1 Novartis Pharmaceuticals Corporation $6,663.11 01/09/2025 Non-covered Recipient Entity
STAT RESEARCH INC
A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SL No dispute reported 06/30/2026 1190310236